REVB (Revelation Biosciences) Other Current Liabilities: $0.00 Mil (As of Mar. 2026)


REVB Revelation Biosciences Inc REVB
28 GF Score
Price $1.04
! 1 Warning Sign
View Full Analysis

What is Revelation Biosciences Other Current Liabilities?

Revelation Biosciences REVB +0.01% 28 Other Current Liabilities is $0.00 Mil as of Mar. 2026. GuruFocus rates REVB with a GF Score™ of 28/100. The stock has 1 warning sign investors should review.

Revelation Biosciences's other current liabilities for the quarter that ended in Mar. 2026 was $0.00 Mil.

Revelation Biosciences's quarterly other current liabilities declined from Sep. 2025 ($0.00 Mil) to Dec. 2025 ($0.00 Mil) but then from Dec. 2025 ($0.00 Mil) to Mar. 2026 ($0.00 Mil).

Revelation Biosciences's annual other current liabilities declined from Dec. 2023 ($0.14 Mil) to Dec. 2024 ($0.00 Mil) but then stayed the same from Dec. 2024 ($0.00 Mil) to Dec. 2025 ($0.00 Mil).

Revelation Biosciences Other Current Liabilities Related Terms

Revelation Biosciences Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Revelation Biosciences's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Revelation Biosciences Other Current Liabilities Chart

Revelation Biosciences Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial 0.00 -0.00 0.14 0.00 0.00

Revelation Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
REVB
28GF Score
Revelation Biosciences Inc REVB
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Revelation Biosciences Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $0.00 Mil mean?
Revelation Biosciences (REVB) has a Other Current Liabilities of $0.00 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Revelation Biosciences.
Is Revelation Biosciences' Other Current Liabilities too high?
Revelation Biosciences' current Other Current Liabilities is $0.00 Mil. Overall, Revelation Biosciences has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Revelation Biosciences' Other Current Liabilities compare to ARTL and ONCO?
Revelation Biosciences' Other Current Liabilities of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Revelation Biosciences. Revelation Biosciences's current Other Current Liabilities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Revelation Biosciences stock overvalued right now?
Revelation Biosciences (REVB) has a current Other Current Liabilities of $0.00 Mil. The current Other Current Liabilities is $0.00 Mil. Revelation Biosciences' overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Revelation Biosciences (REVB), the current Other Current Liabilities is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Revelation Biosciences Business Description

Address 4660 La Jolla Village Drive, Suite 100, San Diego, CA, USA, 92122
Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operates through one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.
28GF Score

Get the complete analysis for REVB

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.04
Price